International Journal of Pharma and Bio Sciences
    ISSN 0975-6299

Int J Pharm Bio Sci Volume 13 issue 2, April - June, Pages:23-28

Rational Use of Medicines and Medication Adherence in Chronic Kidney Disease on Maintenance Hemodialysis.

Mohammed Mansoor Ali , B Rama, Bobburi Tejaswi and Anusha Patil.

Chronic kidney disease is associated with abnormal structural and functional changes in the kidney and its main unit nephrons, which lead to abnormal urine output and impaired excretory function. CKD is also associated with hypertension, diabetes, obesity, and other renal disorders. So After crossing the stages, the renal failure reaches to end-stage renal disorder (ESRD) which is the fifth stage of CKD according to the NKF. Dialysis in the patient individual is done in the end stage, i.e., when the kidney loses its function by about 80 – 90% and when the GFR rate is 15 ml/min. In CKD the maintenance of hemodialysis is done by some medications like antiplatelet (heparin), erythropoietin-stimulating agents, and iron drugs and sometimes if the patient is hypertension, ACE inhibitors are used. A descriptive study, which was conducted on 120 dialysis patients. Data were collected by using a structured questionnaire from December 2020 to June 2021 and then analyzed using SPSS version 20.0 software. Out of the 120 patients who were undergoing dialysis, 83 patients were male and 37 patients were females. According to age group classification, the age group of 40 to 50 years old, or 38 (31.7%), was the most afflicted. CKD (80%) was the most common diagnosis, followed by AKI (10.3%). The most common type of dialysis was an AV fistula (70%) followed by a jugular (25%). The most common comorbidity was hypertension with diabetes mellitus (58.3%) The most common complications were anemia (35.4%) followed by edema (26.24%). Finally, medication adherence was 76.7%. This study indicated that patients who underwent and were undergoing dialysis procedures were majorly affected by CKD. Mostly followed, a type of dialysis was an AV fistula with comorbid condition HTN and diabetes mellitus. The results of the study, which was conducted has minor complications, no major drug interactions, and lower medication adherence, which was developed later by patient education by counseling the patient.

Keywords: Chronic kidney disease, hemodialysis, diabetes, hypertension, heparin, erythropoietin stimulating agents.
Full HTML:


  1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO. Kidney Int. Suppl. 2013; 3, 1–150.
  2. Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, Hobbs FD. Global Prevalence of Chronic Kidney Disease. PLoS One. 2016 Jul 6; 11(7):e0158765.
  3. Masahiko Tozawa, Kunitoshi Iseki, Chiho Iseki, Saori Oshiro, Analysis of drug prescription in chronic haemodialysis patients, Nephrology Dialysis Transplantation. October 2002; Volume 17, Issue 10: Pages 1819–1824.
  4. Mylapuram Rama, Gayathri Viswanathan, Leelavathi D Acharya. Assessment of Drug-Drug Interactions among Renal Failure Patients of Nephrology Ward in a South Indian Tertiary Care Hospital. Indian journal of pharmaceutical sciences. 2012; 74(1): 63–68.
  5. Parker K, Bull-Engelstad I, Aasebø W, von der Lippe N, Reier-Nilsen M, Os I, Stavem K. Medication regimen complexity and medication adherence in elderly patients with chronic kidney disease. Hemodial Int. 2019 Jul; 23(3):333-342.
  6. Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet. 2017 Mar 25; 389(10075):1238-1252.
  7. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N England Journal Medicine. 2004 Sep 23; 351(13):1296-305.
  8. Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J; Chronic Kidney Disease Prognosis Consortium. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011 Jul; 80(1):93-104.
  9. Chukwuonye II, Ohagwu KA, Adelowo OO, Chuku A, Obi EC, Onwuchekwa U, Anyabolu EN, Oviasu E. Prevalence and Predictors of Chronic Kidney Disease in a Semiurban Community in Lagos. Int J Nephrol. 2019 May 2; 1625837.
  10. Singh NP, Ingle GK, Saini VK, Jami A, Beniwal P, Lal M, et al. Prevalence of low glomerular filtration rate, proteinuria and associated risk factors in North India. BMC Nephrol. 2009 Feb 17; 10:4. 
  11. Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. JAMA. 2019 Oct 1;322(13):1294-1304. 
  12. Chronic kidney disease-signs and symptoms [internet].mayo clinic online resources, cited august 2019.
  13. Garland JS. Elevated body mass index as a risk factor for chronic kidney disease: current perspectives. Diabetes Metab Syndr Obes. 2014 Jul 29; 7:347-55.
  14. Hakim RM, Lazarus JM. Initiation of dialysis. Journal of American Society of Nephrology. 1995 Nov; 6(5):1319-28.
  15. Lee KY. A unified pathogenesis for kidney diseases, including genetic diseases and cancers, by the protein-homeostasis-system hypothesis. Kidney Res Clin Pract. 2017 Jun; 36(2):132-144.
  16. Song J.H. Complications of Hemodialysis. In: Kim YL. Kawanishi H. The Essentials of Clinical Dialysis. Springer, Singapore.
  17. Elaine Ku, Benjamin J. Lee, Jenny Wei, Matthew R. Weir, Hypertension in CKD: Core Curriculum 2019, American Journal of Kidney Diseases, Volume 74, Issue 1, 2019, Pages 120-131, ISSN 0272-6386.
  18. Sydney C.W. Tang, Xueqing Yu, Dialysis Care and Dialysis Funding in Asia, American Journal of Kidney Diseases,Volume 75, Issue 5,2020, Pages 772-781,ISSN 0272-6386,
  19. Priyanka Priyanka, Alexander Zarbock, Junichi Izawa, Thomas G. Gleason, Ronny W. Renfurm, John A. Kellum, The impact of acute kidney injury by serum creatinine or urine output criteria on major adverse kidney events in cardiac surgery patients, The Journal of Thoracic and Cardiovascular Surgery, Volume 162, Issue 1,2021,Pages 143-151.e7,ISSN 0022-5223.
  20. Carrero JJ, Hecking M, Chesnaye NC, Jager KJ. Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. Nat Rev Nephrol. 2018 Mar;14(3):151-164. 
  21. Nistala R, Savin V. Diabetes, hypertension, and chronic kidney disease progression: role of DPP4. Am J Physiol Renal Physiol. 2017 Apr 1;312(4):F661-F670.
  22. Raja SM, Seyoum Y. Intradialytic complications among patients on twice-weekly maintenance hemodialysis: an experience from a hemodialysis center in Eritrea. BMC Nephrol. 2020 May 5;21(1):163.
  23. Chakraborty S, Ghosh S, Banerjea A, De RR, Hazra A, Mandal SK. Prescribing patterns of medicines in chronic kidney disease patients on maintenance hemodialysis. Indian J Pharmacol. 2016 Sep-Oct;48(5):586-590.
  24. Foley RN, Curtis BM, Parfrey PS. Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial. Clin J Am Soc Nephrol. 2009 Apr;4(4):726-33.
  25. Garla V, Kanduri S, Yanes-Cardozo L, Lién LF. Management of diabetes mellitus in chronic kidney disease. Minerva Endocrinol. 2019 Sep;44(3):273-287. 
  26. Agrawal A, Kamila S, Reddy S, Lilly J, Mariyala MS. Effect of telmisartan on kidney function in patients with chronic kidney disease: an observational study. J Drug Assess. 2016 Nov 4;5(1):24-28. 
  27. Chirakarnjanakorn S, Navaneethan SD, Francis GS, Tang WH. Cardiovascular impact in patients undergoing maintenance hemodialysis: Clinical management considerations. Int J Cardiol. 2017 Apr 1;232:12-23.




[Download PDF]
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy
Pharmaceutical Fields
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmaceutics
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Novel drug delivery system
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Nanotechnology
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmacology
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmacognosy
© Copyright 2009-2015 IJPBS, India. All rights reserved. Specialized online journals by ubijournal. Website by Ubitech Solutions
         Home I Contact I Terms & Conditions